Harrison.ai vs Qure AI (2026)
Two companies reading chest X-ray and head CT at scale, built on different regulatory strategies. Annalise.ai, a joint venture between an Australian technology firm and a large radiology provider, reads up to 124 findings on chest X-ray and 130 on noncontrast head CT in one pass, with a separately cleared triage portfolio and Medicare new technology payment status. Qure sells chest X-ray, head CT, chest CT and musculoskeletal products in more than 105 countries by its own count, and counts 26 FDA cleared indications across nine products. Its newest US clearance, qXR-Detect (January 2026), is a concurrent reading aid for six categories of chest X-ray findings with a Predetermined Change Control Plan. A US hospital that wants many findings from one pass and a defined reimbursement path looks at Annalise. A buyer that wants chest X-ray detection with a cleared update plan, or tuberculosis screening, looks at Qure.
- Wide coverage per study: up to 124 findings on chest X-ray and 130 on head CT in a single pass.
- A defined US reimbursement path: Medicare new technology payment status, which changes the return calculation for a hospital.
- Triage routing that separates tension pneumothorax, and the first Breakthrough Device designation granted to a radiology triage device.
- A cleared change plan: qXR-Detect's Predetermined Change Control Plan sets out how the model can be updated and how users are told, which the company describes as the only one for a chest X-ray detection device.
- A reader study behind the newest clearance: 18 readers on 301 cases, alongside a standalone test.
- Tuberculosis screening evidence from independent studies in several countries and a 2025 systematic review.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Harrison.ai and Qure AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Harrison.ai | Qure AI |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2019 | 2016 |
| Headquarters | Sydney, Australia | Mumbai, India |
| Website | harrison.ai | qure.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Radiology AI company headquartered in Sydney. Its radiology products were sold as Annalise.ai, including Annalise Enterprise CXR and Annalise Enterprise CTB, until Harrison.ai combined with Annalise.ai in February 2025 and renamed the Annalise.ai solutions Harrison.ai Radiology in October 2025; the annalise.ai domain now forwards to harrison.ai.
Source: AI Health Index, July 2026
Radiology AI company founded in 2016 in Mumbai, with a US entity registered in New York, selling in more than 105 countries through more than 5,500 sites by its own count. Products: qXR for chest X-ray (detection, reporting, lung nodules, tuberculosis screening), qER for head CT in stroke and trauma, qCT for chest CT nodule measurement, qMSK for musculoskeletal X-ray, and heart failure detection.
Source: AI Health Index, July 2026
Questions buyers ask
How do Harrison.ai and Qure AI work with the EHR?
For Harrison.ai, the 510(k) summary for K222268 describes the software receiving DICOM chest X-ray studies from image and order management systems such as a PACS or RIS, running in parallel with the standard workflow, and returning a case level result to the PACS or RIS for worklist prioritization.
With Qure AI, the qXR page promises zero integration effort and deployment on cloud or on premise, the company says its software works with new and old X-ray systems, and the qXR-Detect summary describes results returned to radiology software or the X-ray console; qXR-LN is cleared for use with any DICOM viewer or PACS. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
How are Harrison.ai and Qure AI priced and sold?
In Harrison.ai's case, the products are sold to healthcare organizations (public hospitals, private hospitals and private radiology providers) by contacting the company, and the site states they are not available for purchase by the general public.
For Qure AI, the portfolio is what makes the silence bite. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
How do Harrison.ai and Qure AI handle patient data?
With Harrison.ai, the company's privacy notice (last updated 20 November 2025), which covers its products and services as well as its websites, states that it does not use any content uploaded into its services, including demos, product trials and evaluations, for model training.
Qure's Security and Regulatory page says data is de-identified before it leaves a covered entity's premises for cloud processing, and that on-premise installations may process identifiable images only on servers the customer owns and operates. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
Which settings and specialties do Harrison.ai and Qure AI cover?
For Harrison.ai, the company sells chest X-ray (up to 124 findings), non contrast head CT (up to 130 findings) and chest CT (up to 167 radiological features) to public hospitals, private hospitals and private radiology providers, with solution pages for emergency and acute care and for oncology management, and states clearance for clinical use in more than 40 countries. The US triage clearances carry defined, validated populations.
Qure covers chest X-ray, head and chest CT and musculoskeletal X-ray, sold to hospitals, imaging centers, teleradiology services, immigration screening and public health programs in more than 105 countries. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified July 22, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Annalise.ai's record has not yet been reviewed on this site, so its side of this page rests on the build record. Its reported 32 percent head CT accuracy improvement has no published study detail.
Qure's US summaries report area under the curve or sensitivity without the number of scans tested, so ask for the case counts. Qure also markets sorting out unremarkable chest X-rays and does not say who reads the studies set aside; that use is outside its US clearances. Chest X-ray AI performance varies with equipment and patient group, so ask both for results on your own scanners and population. Qure states its cloud path receives only images stripped of identifiers; ask Annalise for its business associate terms and where inference runs.